Search hospitals > Washington > Seattle
Seattle Cancer Care Alliance
Claim this profileSeattle, Washington 98109
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Prostate Cancer
Conducts research for Tumors
426 reported clinical trials
43 medical researchers
Summary
Seattle Cancer Care Alliance is a medical facility located in Seattle, Washington. This center is recognized for care of Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Prostate Cancer, Tumors and other specialties. Seattle Cancer Care Alliance is involved with conducting 426 clinical trials across 457 conditions. There are 43 research doctors associated with this hospital, such as Michael Schweizer, Michael J Wagner, MD, Christina S. Baik, and Andrew L. Coveler.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
HER2 negative
Stage III
Top PIs
Michael SchweizerFred Hutch/University of Washington Cancer Consortium4 years of reported clinical research
Expert in Prostate Cancer
Studies Prostate Adenocarcinoma
13 reported clinical trials
26 drugs studied
Michael J Wagner, MDFred Hutchinson Cancer Research Center4 years of reported clinical research
Studies Liposarcoma
Studies Sarcoma
13 reported clinical trials
19 drugs studied
Christina S. BaikFred Hutchinson Cancer Research Center5 years of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
10 reported clinical trials
18 drugs studied
Andrew L. CovelerFred Hutchinson Cancer Research Center4 years of reported clinical research
Studies Pancreatic Cancer
Studies Pancreatic Adenocarcinoma
10 reported clinical trials
22 drugs studied
Clinical Trials running at Seattle Cancer Care Alliance
Non-Small Cell Lung Cancer
Cancer
Prostate Cancer
Lung Cancer
Breast Cancer
Lymphoma
Tumors
Myelodysplastic Syndrome
Ovarian Cancer
Leukemia
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Ramucirumab + Pembrolizumab vs Chemotherapy
for Non-Small Cell Lung Cancer
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out if giving ramucirumab with pembrolizumab is more effective at treating patients with stage IV or recurrent non-small cell lung cancer than standard chemotherapy.
Recruiting2 awards Phase 310 criteria
U3-1402
for Non-Small Cell Lung Cancer
This trial is testing HER3-DXd, a new drug for advanced lung cancer patients who haven't responded to other treatments. The drug targets a protein on cancer cells and delivers a toxic substance to destroy them.
Recruiting1 award Phase 118 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Seattle Cancer Care Alliance?
Seattle Cancer Care Alliance is a medical facility located in Seattle, Washington. This center is recognized for care of Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Prostate Cancer, Tumors and other specialties. Seattle Cancer Care Alliance is involved with conducting 426 clinical trials across 457 conditions. There are 43 research doctors associated with this hospital, such as Michael Schweizer, Michael J Wagner, MD, Christina S. Baik, and Andrew L. Coveler.
Where is Seattle Cancer Care Alliance located?
**Seattle Cancer Care Alliance**
- **Address:** 825 Eastlake Ave E, Seattle, WA.
Who should I call to ask about financial aid or insurance network?
Seattle Cancer Care Alliance (SCCA) provides financial assistance to eligible patients, including those with health insurance, based on income requirements. Patients interested in applying for financial assistance can contact the facility directly or submit an application. For assistance with insurance benefits and care options, SCCA's Patient Financial Services team is available at 800.304.1763.
What insurance does Seattle Cancer Care Alliance accept?
Seattle Cancer Care Alliance (SCCA) accepts a wide range of insurance plans, including but not limited to Premera Blue Cross, Regence BlueShield, Kaiser Permanente, and Medicare. It is important to verify coverage with your insurance provider as some plans, especially those from the Washington Healthplanfinder, may not cover cancer treatment at SCCA. SCCA is also in-network with numerous other insurance providers such as Boeing BCBS, Cigna PPO, Community Health Plan of Washington, and many more. Always confirm that your plan covers the necessary care at SCCA before scheduling an appointment.
What awards or recognition has Seattle Cancer Care Alliance received?
Seattle Cancer Care Alliance (SCCA) ranks among the top ten cancer hospitals in the nation, according to U.S. News & World Report, and is the leading cancer hospital in the Pacific Northwest. It has earned "High Performing" ratings for both colon cancer surgery and lung cancer surgery, showcasing care that surpasses the national average.